🌍·Aug 31Research
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)
Publisher
C
Crossref
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Crossref
- Region
- Global
- Scope
- Research
- Published
- August 31, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on doi.org
Leave the platform to read the original full article on the publisher site.
Source: Crossref
Scope: Research
Related coverage
More related coverage
Crossref/14h ago
Evaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patients
Crossref/14h ago
Polycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Prediction
Crossref/14h ago
Low-Dose Silodosin for Premature Ejaculation: A Clinical Evaluation
Crossref/14h ago